These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23320520)

  • 1. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain.
    Krarup AL; Ny L; Gunnarsson J; Hvid-Jensen F; Zetterstrand S; Simrén M; Funch-Jensen P; Hansen MB; Drewes AM
    Scand J Gastroenterol; 2013 Mar; 48(3):274-84. PubMed ID: 23320520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heartburn sensation in nonerosive reflux disease: pattern of superficial sensory nerves expressing TRPV1 and epithelial cells expressing ASIC3 receptors.
    Ustaoglu A; Sawada A; Lee C; Lei WY; Chen CL; Hackett R; Sifrim D; Peiris M; Woodland P
    Am J Physiol Gastrointest Liver Physiol; 2021 May; 320(5):G804-G815. PubMed ID: 33655767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
    Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
    Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.
    Manabe N; Haruma K; Ito M; Takahashi N; Takasugi H; Wada Y; Nakata H; Katoh T; Miyamoto M; Tanaka S
    Dis Esophagus; 2012 Jul; 25(5):373-80. PubMed ID: 22050449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Traditional Chinese medicine based on Tongjiang methodology combined with proton pump inhibitor (PPI) step-down in treating non-erosive reflux disease: a study protocol for a multicentered, randomized controlled clinical trial.
    Li X; Wu H; Zhang B; Chen T; Shi X; Ma J; Zhang J; Tang X; Wang F
    Trials; 2022 Oct; 23(1):879. PubMed ID: 36258217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
    Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG
    Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment.
    Tack J; Zerbib F; Blondeau K; des Varannes SB; Piessevaux H; Borovicka J; Mion F; Fox M; Bredenoord AJ; Louis H; Dedrie S; Hoppenbrouwers M; Meulemans A; Rykx A; Thielemans L; Ruth M
    Neurogastroenterol Motil; 2015 Feb; 27(2):258-68. PubMed ID: 25530111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of proton pump inhibitors in nonerosive reflux disease.
    Dean BB; Gano AD; Knight K; Ofman JJ; Fass R
    Clin Gastroenterol Hepatol; 2004 Aug; 2(8):656-64. PubMed ID: 15290657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist.
    Brown W; Leff RL; Griffin A; Hossack S; Aubray R; Walker P; Chiche DA
    J Pain; 2017 Jun; 18(6):726-738. PubMed ID: 28188907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile.
    Arendt-Nielsen L; Harris S; Whiteside GT; Hummel M; Knappenberger T; O'Keefe S; Kapil R; Kyle D
    Pain; 2016 Sep; 157(9):2057-2067. PubMed ID: 27168361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.
    Limsrivilai J; Charatcharoenwitthaya P; Pausawasdi N; Leelakusolvong S
    Am J Gastroenterol; 2016 Feb; 111(2):217-24. PubMed ID: 26753892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.
    Miner PB; Silberg DG; Ruth M; Miller F; Pandolfino J
    BMC Gastroenterol; 2014 Nov; 14():188. PubMed ID: 25407279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: a prospective multicenter study.
    Park CH; Seo SI; Kim JS; Kang SH; Kim BJ; Choi YJ; Byun HJ; Yoon JH; Lee SK
    Sci Rep; 2020 Sep; 10(1):15154. PubMed ID: 32938975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study.
    Zhang J; Che H; Zhang B; Zhang C; Zhou B; Ji H; Xie J; Shi X; Li X; Wang F; Tang X
    Phytomedicine; 2021 Jul; 88():153584. PubMed ID: 34119741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers.
    Lee J; Kim BH; Yu KS; Kim HS; Kim JD; Cho JY; Lee S; Gu N
    Drug Des Devel Ther; 2017; 11():1301-1313. PubMed ID: 28479852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn.
    Zerbib F; Sacher-Huvelin S; Coron E; Coffin B; Melchior C; Ponchon T; Cholet F; Chabrun E; Vavasseur F; Gorbatchef C; Zalar A; Mion F; Robaszkiewicz M; Le Rhun M; Leroy M; Paul Galmiche J; Bruley des Varannes S
    Aliment Pharmacol Ther; 2020 Aug; 52(4):637-645. PubMed ID: 32656869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial.
    Rowbotham MC; Nothaft W; Duan RW; Wang Y; Faltynek C; McGaraughty S; Chu KL; Svensson P
    Pain; 2011 May; 152(5):1192-1200. PubMed ID: 21377273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease.
    Park SH; Lee KN; Lee OY; Choi MG; Kim JH; Sung IK; Jang JY; Park KS; Chun HJ; Kim EY; Lee JK; Jang JS; Kim GH; Hong SJ; Lee YC; Choi SC; Kim HS; Kim TO; Baik GH; Jeon YC
    Gut Liver; 2023 Mar; 17(2):226-233. PubMed ID: 35730245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narrow-band imaging for the diagnosis of nonerosive reflux disease: an international, multicenter, randomized controlled trial.
    Desai M; Srinivasan S; Sundaram S; Dasari C; Andraws N; Mathur S; Higbee A; Miller J; Beg S; Fateen W; Sami SS; Repici A; Ragunath K; Sharma P
    Gastrointest Endosc; 2022 Sep; 96(3):457-466.e3. PubMed ID: 35487299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation.
    Savarino V; Pace F; Scarpignato C;
    Aliment Pharmacol Ther; 2017 Mar; 45(5):631-642. PubMed ID: 28116754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.